Document is current

Any future updates will be listed below

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system

Crossref DOI link: https://doi.org/10.1038/s41598-025-86959-z

Published Online: 2025-01-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark